Joe Flanagan has returned as CEO of R1 RCM following the completion of TowerBrook Capital Partners and Clayton, Dubilier & Rice’s $8.9 billion deal to take the company private.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
